the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery

Published by Decision Resources, Inc. Contact us : +1-860-674-8796
Published 2007/05 Content info 26 Pages
Product code DR52447
Price From  US $ 1112 Order/Price list
US $ 1112 PDF by E-mail (Single User License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Abstract

Introduction

Protein biomarkers are appealing to drug developers because they can be used early in the drug research pipeline, which allows early elimination of ineffective or toxic compounds. Although the promise of these biomarkers is clear, the path to successful implementation of protein biomarkers is not. Perhaps the discovery-based approach is not the best way to tap the potential of protein biomarkers.

Get the Answers You Need to Shape Your Strategy

  • Despite scientifi c advancements, protein biomarker discovery is slowing. What are the challenges facing companies and researchers that are hindering the discovery process?
  • Researchers are rethinking the discovery-based approach. What other options and innovations are available? What companies are leading the way?
  • The future of protein biomarkers is extremely promising for a multitude of businesses. What benefi ts are available for technology vendors, Big Pharma companies, researchers, and regulatory agencies? Can collaboration between any or all of these stakeholders ensure the success of protein biomarkers?

Scope

  • Proteomics technologies: 2D PAGE, mass spectrometry, antibody microarrays, microfl uidics, label-free technologies.
  • Alternatives to discovery-based approach: hypothesis-based approach, engineering better biomarkers, systems biology.
  • Major players in protein biomarker discovery: Bayer, Eli Lilly, Novartis, Pfi zer, Roche.
  • Outlook: The path toward successful protein biomarker discovery may include multiplexing strategies, collaborations among researchers and developers, and support from regulatory bodies.

Companies Mentioned in This Spectrum Report

  • Applied Biosystems
  • Axis Shield
  • Bayer Pharmaceuticals
  • Beyond Genomics
  • Biacore
  • Bioforce Nanoscience
  • Bio-Rad
  • Biosite
  • Bruker Daltonics
  • Cantion
  • Clontech
  • CODA Genomics
  • Eisai
  • Eli Lilly
  • Fujirebio
  • Gene News
  • Genedata
  • GeneProt
  • Geneva Proteomics
  • Genomic Solutions
  • Genoptics
  • GenTel Biosciences
  • Integrated Genomics
  • Invitrogen
  • Johnson & Johnson
  • Lumera
  • Matritech
  • Microfl uidics
  • Millennium Pharmaceuticals
  • Pfi zer
  • Phadia US
  • Power3 Medical Products
  • Predictive Diagnostics
  • Proteome Systems
  • Quadraspec
  • RBM
  • Roche
  • Rosetta Inpharmatics
  • Sareum
  • Shimadzu
  • Target Discovery
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.